I like what I see here. “From a mechanistic

I like what I see here.


“From a mechanistic standpoint, we believe we could get a synergistic effect with a checkpoint inhibitor,” he said.

Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center.

Arman said CytoDyn expects to observe an enhanced anti-tumor effect from the combination and identify immunological biomarkers.

In terms of future partnerships, Arman isn’t concerned that CytoDyn’s history will have a negative effect.

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech

Principal Investigator:
FG001|FG002|FG003

https://zenodo.org/records/17290045?token=eyJ...UkeT_EvKIQ


https://firegatebiotech.com/2025

https://zenodo.org/records/17291133?token=eyJ...kN7msthgMA





— Jeremiah 51:36